The Transfusion Chip: Phase II Technology Validation

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 2R44HL110442-02
Agency Tracking Number: R44HL110442
Amount: $1,732,966.00
Phase: Phase II
Program: SBIR
Awards Year: 2013
Solicitation Year: 2013
Solicitation Topic Code: NHLBI
Solicitation Number: PA12-088
Small Business Information
3450 S. Broadmont, TUCSON, AZ, 85710-
DUNS: 141832860
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 (520) 904-1715
Business Contact
Phone: (847) 359-1032
Research Institution
DESCRIPTION (provided by applicant): Blood-Typing is the progenitor of the entire field of personalized medicine. In the recently awarded 6-month Phase I, we proposed to take the first step in the development of an extremely-low-cost microarray test, TheTransfusion-Chip (T-Chip) which convert the historical practice of Blood-Typing by serology into a simple inexpensive DNA test. Here, in this follow-on Phase II, we demonstrate substantial success in achieving key Phase I milestones: we have developed andoptimized 22 PCR reactions, comprising the entire 7 gene blood group gene set [ABO, Rh, Duffy, Kidd, Kell, Dombrock and MNS]; we have fabricated a Transfusion-Chip microarray prototype capable of analyzing all known genetic variation in the 7 gene set; and via technology that we had not yet invented when we filed the Phase I, we have developed a new variant of the original GenUSA microarray test which will drop the manufacturing cost of T-Chips to values as low as 1 per microarray. In Phase I we have also shown that the raw, unpurified OrageneTM-stabilized saliva can used as the basis for DNA based Blood-Typing on the T-Chip. We feel that the coupling of raw OrageneTM-stabilized saliva collection with the low cost T-Chip could become a unique technology pairing: because it would allow self-collection of DNA samples, at home, then low- cost ambient temperature shipping to centralized labs, to be followed by very-low-cost, very high throughput Blood-Typing on T-Chips. This model for population scale Blood-Typing will be the development focus in this Phase II: thereby enabling, we propose, an entirely new vision for population-scale blood banking and transfusion medicine, and in the process, will allow Blood- Typing to return, in the 21st century, to prominence as the model and gold standard for the field of genetically personalized medicine: as it first did a hundred years ago. Based on that model for population-scale blood group genetic testing, we propose the following set of Phase II Aims. SA1. Complete andValidate the Multiplex PCR Front-end to the Transfusion-Chip, for DNA Samples. SA2. Complete and Validate the Multiplex PCR Front-end to the Transfusion-Chip, for Raw Samples. SA3. Optimize and validate fabrication of the Transfusion-Chip in the 48 arrayper slide 1 microarray format. SA4. Modify existing GenUSA analysis software, RicimerTM, for automated blood group typing. SA5. Validate the Transfusion-Chip for purified DNA, raw blood and raw OrageneTM-stabilized saliva samples. Phase II Deliverablesand Commercialization Plan. Upon completion of this Phase II, we will have ready a Transfusion-Chip kit prototype (microarrays, PCR reagents, Hybridization Reagents, Specialized Software) for subsequent Beta Testing. This kit will be prepared under manufacturing control (ISO 13845) similar to the HLA-Chip products from GenUSA which are currently being launched into tissue compatibility and immunogenetics markets. Subsequent to completion of Phase II, GenUSA will launch the T-Chip into the RUO Blood-Typingmarket and prepare simultaneously for FDA 510(k) submission to enter into the diagnostics market either alone, or in partnership with those with a proven market presence in transfusion medicine or at-home sample collection, or both. PUBLIC HEALTHRELEVANCE PUBLIC HEALTH RELEVANCE: Blood group antigen typing by serology (Blood-Typing) has been, for a century, the progenitor and gold standard for the entire field of personalized medicine. Here we propose to pair two technologies recently developedat GenUSA [Raw Sample Genotyping + 1 Microarrays] to allow Blood-Typing to become a low-cost genetic test: A saliva or a dried blood sample could be self-collected at home in a simple clinic, then shipped by ordinary book-rate mail to a central lab, whereupon arrival in the lab, Blood-Typing would be performed inexpensively via 1 microarray testing . We propose that this new vision for very-large-scale public health genetics will not only revolutionize the regulation of the blood supply and the practiceof transfusion medicine, but will also serve as a model for a new approach to genetically personalized medicine: much as Blood-Typing, by serology, created (personalized) Transfusion Medicine a century ago.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government